Baseline Characteristics
coronavirus disease 2019
CORONAVIRUS DISEASE 2019
Abbreviations: BP, blood pressure; CRP, C-reactive protein; GLP-1, glucagon-like peptide-1; HbACalculated as weight in kilograms divided by height in meters squared.Race and ethnicity data were collected via patient self-report and reported to accurately describe the study population.Other race and ethnicity groups included African, Asian British, Bangladeshi, Caribbean, Chinese, Indian, Pakistani, White British, White Irish, multiple races or ethnicities, and others, consolidated owing to small numbers.Fat mass, lean mass, and bone mass were recorded using dual energy X-ray absorptiometry; 2 values are missing from the liraglutide group.Three participants (4.3%), 1 (2.9%) in the placebo group, and 2 (5.7%) in the liraglutide group, were lost to follow-up. In the placebo group, 5 participants discontinued treatment but all continued to provide data. Two participants from the liraglutide group discontinued treatment, and 1 continued to provide data. All participants who completed the trial escalated to 3.0 mg once daily. Due to lockdown restrictions following the emergence of the coronavirus disease 2019 pandemic, 7 participants were unable to attend the clinic for their final body weight measurements. Additionally, 2 participants could not attend due to other health reasons, resulting in 31 participants in the liraglutide, 3.0 mg, group in the primary intention-to-treat analysis and 26 in the placebo group. Lockdown measures impacted upon conduct of final visit blood tests, dual energy X-ray absorptiometry, and physical functional testing.From baseline to week 24, a greater reduction in percentage body weight was observed in the 3.0-mg liraglutide group compared with the placebo group (mean [SD], −8.82 [4.94] vs −0.54 [3.32], respectively; 